Injectable Drug Delivery News

  1. Berkshire Sterile Provides A New Offering For Small Volume Filling 10/14/2022

    Berkshire Sterile Manufacturing (BSM), a Massachusetts fill finish CMO, recently developed a new sterile filling process designed to reduce product loss for high-value drug product candidates. The process is intended for customers that have limited drug product and need to conserve every drop. It is additionally well suited for customers that have very small volume delivery needs with excellent precision. Filling is entirely isolator-based, easy to operate, and has demonstrated superior repeatability and accuracy.

  2. Stevanato Group Collaborates With IL Group To Improve Safe Processing And Handling Of Hazardous Injectable Drugs 10/12/2022

    The new integrated solution will leverage high-value solutions for drug containment (vials) and container protection (labels) to improve and facilitate the handling and storage of sensitive drugs, as well as ensure higher levels of safety for healthcare professionals and patients.

  3. scPharmaceuticals Announces FDA Approval Of FUROSCIX® (Furosemide Injection) 10/11/2022

    scPharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has approved FUROSCIX® (furosemide injection), a proprietary formulation of furosemide delivered via an On-Body Infusor for the treatment of congestion due to fluid overload in adults with New York Heart Association Class II/III chronic heart failure.

  4. Aktiv Pharma Group To Participate In The FDA Emerging Technology Program 9/26/2022

    Aktiv Pharma Group (Aktiv) announced today the acceptance of its novel glass-free, film-based flexible primary drug container (PDC) technology for sterile injectables named ARCH, into the US Food and Drug Administration (FDA) Emerging Technology Program (ETP)

  5. ten23 Health Completes The Superstructure Of Their New Large-Scale Sterile Production Facility In Visp, Switzerland 9/19/2022

    With the initial phase of construction now complete, ten23 will commence with interior construction andhiring of further team members. The sterile manufacturing plant is well on track to be operational in 2024 for global commercial supplies of injectable drugs

  6. Grand River Aseptic Manufacturing To Fill And Finish Smallpox/Monkeypox Vaccines And Accelerate Domestic Supply 8/19/2022

    Grand River Aseptic Manufacturing (“GRAM”), a prominent parenteral drug product contract development and manufacturing organization (CDMO), has entered into an agreement with Bavarian Nordic, a Denmark-based vaccine company, to fill and finish JYNNEOS smallpox/monkeypox vaccine

  7. Grand River Aseptic Manufacturing Completes Phase II Expansion With Installation Of Two New Sterile Filling Lines 8/17/2022

    Grand River Aseptic Manufacturing (“GRAM”), a prominent parenteral drug product contract development and manufacturing organization (CDMO), has completed Phase II of its facility expansion which includes the installation of GRAM’s two new sterile Bausch+Ströbel filling lines

  8. West Makes Minority Investment In Dublin-Based Latch Medical, A Developer Of Vaccine And Biologics Delivery Platforms 8/15/2022

    West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced it has made a strategic investment in Latch Medical, a Dublin-based leader in next-generation vaccine and biologics delivery technology that is pioneering a new approach to intradermal delivery.

  9. Landec Corporation Announces Intention To Become Lifecore Biomedical 8/10/2022

    Landec Corporation (Nasdaq: LNDC) (“Landec” or the “Company”), a diversified health and wellness company focused on its growing Lifecore Biomedical (“Lifecore”) business – a fully integrated contract development and manufacturing organization (“CDMO”) that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials – today formally announced the Company’s path forward as a CDMO-focused life sciences company, complete with a planned corporate rebranding, new ticker symbol, and the naming of its go-forward executive leadership team and Board of Directors

  10. Genixus Receives Federal Registration & State Licensing To Begin Production Of KinetiX™ Ready-To-Administer (RTA) Syringe Platform For Acute And Critical Care Medicines 8/3/2022

    Genixus, a pharmaceutical company focused on transforming acute and critical care medicines, today announced that it has received both federal registration and state licensing to begin commercial production of its new KinetiX™ RTA Platform brand of pre-filled syringes